Many Anticancer Targets Could Be A Mirage

Reading time: 4 minutes Kedar Puvar Designing new anticancer compounds is often a deliberate process, where the mechanism of action involves the blocking of a certain target, like a receptor or other cellular protein. Researchers would then optimize potential leads until a potent and effective drug is ready for clinical trials. This pipeline is considered... Continue Reading →

The Reproducibility Crisis

Morgan McSweeney As Alex Woodell recently described, the preclinical research community is in a quiet crisis. Somewhere between 50% and 90% of results from early-stage academic cancer research are unable to be reproduced by industry scientists. Studies by several large multinational pharmaceutical companies and a number of other independent research groups have confirmed what they... Continue Reading →

Create a website or blog at WordPress.com

Up ↑